Thanakorn Piadaeng/iStock via Getty Images
Following the release of encouraging long-term data from a Phase 1 trial of its CRISPR-based gene therapy NTLA-2002 for hereditary angioedema (HAE) treatment, Intellia Therapeutics’ (NASDAQ:NTLA) shares surged by 13% on Monday.
In a press release, the biotech company revealed that the monthly attack rate saw a mean decrease of 98% after administering a single dose of NTLA-2002, based on an average 20-month follow-up across all patients. They further reported that eight out of ten patients had no attacks after a 16-week primary observation period through the last follow-up, which included patients suffering from the most acute disease.
Over the weekend, the data was presented by Intellia at the 2024 European Academy of Allergy and Clinical Immunology Congress held in Spain.
Intellia anticipates releasing the Phase 2 results of the therapy by mid-year and expects a crucial Phase 3 trial to commence during the latter half of 2024, pending regulatory feedback.
Additional Information on Intellia Therapeutics
Source link
This article was complied with AI assistance and reviewed by an editor. More information can be found in our T &C
